Royalty Pharma (RPRX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Royalty Pharma

    NASDAQ: RPRX · Real-Time Price · USD
    37.05
    0.15 (0.41%)
    At close: Sep 05, 2025, 1:01 PM

    Royalty Pharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 2.26B 2.35B 2.24B 2.29B
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 2.26B 2.35B 2.24B 2.29B
    Operating Income
    		 1.29B 1.49B 307.06M 1.43B
    Interest Income
    		 47.34M 72.29M 78.33M 53.53M
    Pretax Income
    		 1.33B 1.7B 230.06M 1.24B
    Net Income
    		 858.98M 1.13B 42.83M 619.73M
    Selling & General & Admin
    		 236.67M 249.75M 227.3M 182.83M
    Research & Development
    		 2M 52M 177.11M 200.08M
    Other Expenses
    		 732.46M 560.66M 1.53B 475.84M
    Operating Expenses
    		 971.13M 862.4M 1.93B 858.75M
    Interest Expense
    		 225.51M 187.19M 187.96M 166.14M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 971.13M 862.4M 1.93B 858.75M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 445.99M 447.6M 437.96M 414.79M
    Shares Outstanding (Diluted)
    		 594M 602.9M 437.97M 414.8M
    EPS (Basic)
    		 1.93 2.54 0.10 1.49
    EPS (Diluted)
    		 1.45 2.53 0.10 1.49
    EBITDA
    		 1.56B 1.89B 423.69M 1.43B
    EBIT
    		 1.56B 1.89B 418.02M 1.41B
    Depreciation & Amortization
    		 n/a n/a 5.67M 23M

    Add to Watchlist